Clincosm LogoSign in Get a demo

central nervous system lymphoma

Showing 1 - 25 of 31
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

CNS Lymphoma Trial in China (Selinexor, Rituximab, Methotrexate)

Not yet recruiting
  • Central Nervous System Lymphoma
  • Hefei, Anhui, China
  • +4 more
Jan 26, 2023

CNS Lymphoma, DLBCL Trial in United States (Lenalidomide, Methotrexate, Nivolumab)

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Los Angeles, California
  • +42 more
Jan 26, 2023

CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)

Recruiting
  • Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,

Recruiting
  • Waldenstrom Macroglobulinemia
  • +8 more
  • Iopofosine I 131 single dose
  • +2 more
  • Redlands, California
  • +42 more
Dec 30, 2022

CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)

Recruiting
  • Central Nervous System Lymphoma
  • Human CD19-CD22 Targeted T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022

CNS Lymphoma Trial in Duarte (procedure, biological, drug)

Recruiting
  • Central Nervous System Lymphoma
  • Aspiration
  • +10 more
  • Duarte, California
    City of Hope Medical Center
Dec 8, 2022

CNS Lymphoma Trial in Aarhus (Immunochemo)

Completed
  • Central Nervous System Lymphoma
  • Aarhus, Denmark
    Elisa Jacobsen Pulczynski
Aug 3, 2022

Study of First Ever Ischemic Stroke in Central Norway

Active, not recruiting
  • Stroke
  • +8 more
  • no intervention
  • Kristiansund, Norway
  • +7 more
Jun 9, 2022

CNS Lymphoma Trial in Petah Tikva (Imbruvica)

Recruiting
  • Central Nervous System Lymphoma
  • Petah Tikva, Israel
    Hematology Institute
May 9, 2022

CNS Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Houston (Akt/ERK Inhibitor ONC201,

Terminated
Has Results
  • Central Nervous System Lymphoma
  • +6 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 30, 2022

CNS Lymphoma Trial in Chapel Hill, Winston-Salem (Acalabrutinib, Isavuconazole)

Recruiting
  • Central Nervous System Lymphoma
  • Chapel Hill, North Carolina
  • +1 more
Mar 24, 2022

CNS Lymphoma Trial in Seongnam-si (lenalidomide)

Recruiting
  • Central Nervous System Lymphoma
  • Seongnam-si, Please Select, Korea, Republic of
    Seoul National University Bundang Hospital
Feb 18, 2022

CNS Lymphoma Trial in Zhengzhou (ICP-022, Pemetrexed)

Recruiting
  • Central Nervous System Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jan 28, 2022

CNS Lymphoma, Non-Hodgkin Lymphoma Trial in Berlin

Recruiting
  • Central Nervous System Lymphoma
  • Non-Hodgkin Lymphoma
    • Berlin, Germany
      Charité - Universitätsmedizin, Med. Klinik m. S. Hämatologie, On
    Nov 8, 2021

    Diffuse Large B Cell Lymphoma, CNS Lymphoma Trial in Beijing (Methotrexate)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Central Nervous System Lymphoma
    • Beijing, Beijing, China
      Peking union medical college hospital
    Sep 21, 2021

    CNS Lymphoma Trial in United States (drug, other, biological)

    Active, not recruiting
    • Central Nervous System Lymphoma
    • Cincinnati, Ohio
    • +3 more
    Sep 15, 2021

    After Whole Brain Radiation Therapy for Hematologic Malignancies

    Recruiting
    • Central Nervous System Lymphoma
    • +5 more
    • Magnetic Resonance Imaging
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 12, 2021

    CNS Lymphoma Trial in Zhengzhou (Rituximab, Lenalidomide, Zanubrutinib, Lenalidomide, Zanubrutinib, Lenalidomide)

    Recruiting
    • Central Nervous System Lymphoma
    • Rituximab, Lenalidomide, Zanubrutinib
    • +2 more
    • Zhengzhou, Henan, China
      Henan cancer hospital
    Jun 16, 2021

    CNS Lymphoma Trial (chidamide combined with rituximab and high-dose methotrexate)

    Not yet recruiting
    • Central Nervous System Lymphoma
    • chidamide combined with rituximab and high-dose methotrexate
    • (no location specified)
    Aug 14, 2020

    B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, CNS Lymphoma, Intraocular

    Completed
    • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
    • +5 more
    • Scottsdale, Arizona
    • +6 more
    Jul 18, 2019

    Lymphomas of the Central Nervous System (ALYCE-molecular)

    Unknown status
    • Central Nervous System Lymphoma
    • Retrospective study
    • Pierre-Bénite, France
      Service d'hématologie biologique - Centre Hospitalier Lyon Sud -
    Feb 28, 2019

    AIDS-related Primary Central Nervous System Lymphoma Treated

    Completed
    • Central Nervous System Lymphoma
    • AIDS Related Lymphoma
    • Retrospective survival analysis
    • Paris, France
      Fondation Ophtalmologique A. de Rotchschild
    Sep 28, 2018

    CNS Lymphoma, Malignant Glioma, Metastatic Malignant Tumor in the Brain Trial in Portland (3 Tesla Magnetic Resonance Imaging,

    Unknown status
    • Central Nervous System Lymphoma
    • +2 more
    • 3 Tesla Magnetic Resonance Imaging
    • +5 more
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Jun 28, 2018